Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer

Summary

Most patients with advanced ovarian cancer suffered recurrences. Therefore, adjuvant therapy is recommended for all patients with advanced ovarian cancer. Traditionally, intravenous paclitaxel + carboplatin has been the standard adjuvant therapy. Recently, intraperitoneal combination chemotherapy has been reported to be effective in ovarian cancer. We attempted to evaluate the efficacy and feasibility of standard intravenous paclitaxel + carboplatin plus intraperitoneal paclitaxel chemotherapy.

Timeline

Start

2007-05

Primary completion

2010-10

Completion

2010-10

Outcome

Outcome not reported

Stopped (Enrollment): “This study stopped due to slow accrual.”

Drugs

Indications